Patients were randomly assigned to receive either 6 cycles of R-CHOP or 6 cycles of R-CHOP alternating with rituximab, dexamethasone, cytarabine
prednisone. (R-CHOP) plus bevacizumab to R-CHOP without bevacizumab. While No clinically relevant interaction of co-administered chemotherapy on Avastin.
The most common combination of drugs used to treat DLBCL is called R-CHOP. R-CHOP includes the following drugs: rituximab: one of a group of drugs called
vincristine sulfate, prednisone (CHOP) and R-EPOCH, prior are - Participants who have had chemotherapy other than R-EPOCH or R-CHOP, or radiotherapy
SEQUENCE OF MEDICATION ADMINISTRATION – R-CHOP (Cycles 1, 3 and 5). Pre-treatment Requirements – R-CHOP (Cycles 1, 3 and 5). Drug. Dose. CCMB
blood; PLTs, platelets. All patients met criteria for predicted prednisone (R-CHOP), R-CHOP followed by RICE, doxorubicin, bleomycin
The addition of an extra drug to the conventional first line R-CHOP regimen in patients with DLBCL resulted in a trend towards improved disease control compared to standard R-CHOP. However, there was no significant change in response rates or OS, and R-CHOP X was associated with an increased risk for serious and grade III/IV hematological
This clinical trial compared rituximab / cyclophosphamide / doxorubicin / vincristine / prednisone (R-CHOP) plus Avastin to R-CHOP without. Avastin. While
The addition of an extra drug to the conventional first line R-CHOP regimen in patients with DLBCL resulted in a trend towards improved disease control compared to standard R-CHOP. However, there was no significant change in response rates or OS, and R-CHOP X was associated with an increased risk for serious and grade III/IV hematological
Comments